303results about How to "Accelerated death" patented technology

Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of LAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inbhibitors, NSAIDs, taxanes and platinum containing compounds use broader language

A method of improving the growth and / or pathogen resistance of a plant, comprising the step of exposing at least part of the plant to a transient period of high intensity illumination providing a photon flux at the plant surface having at least one of the following characteristics: (a) a red photon flux comprising at least 100 micromoles photons per square metre per second, and having a wavelength of between 600 and 700 nm; (b) a blue photon flux comprising at least 100 micromoles photons per square metre per second, having a wavelength of between 420 and 480 nm. The Invention also provides apparatus for providing such conditions to growing plants.

A system and method of preparing medical care instructions for an individual in an emergency situation. The system and method includes obtaining patient information, providing a mechanism to educate the individual on medical and legal terms and procedures, to create medical care instructions, applying the patient information to applicable legal and medical standards and providing a mechanism for updating and maintaining the medical care instructions. The system and method further includes storing the medical care instructions in electronic format, such as on a central computerized database, and allowing immediate and secure access to the stored medical care instructions by medical personnel. The stored medical care instructions may also be outputted when necessary.

The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and / or endothelial cells, particularly interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of an effective amount of one or more agents that are antagonists of EphA2. In certain embodiments, the EphA2 antagonistic agent of the invention decreases EphA2-endogenous ligand binding, upregulates EphA2 gene expression and / or translation, increases EphA2 protein stability or protein accumulation, decreases EphA2 cytoplasmic tail phosphorylation, promotes EphA2 kinase activity (other than autophosphorylation or ligand-mediated EphA2 signaling), increases proliferation of EphA2 expressing cells, increases survival of EphA2 expressing cells, and / or maintains / reconstitutes epithelial and / or endothelial cell layer integrity. The invention also provides pharmaceutical compositions comprising one or more EphA2 antagonistic agents of the invention either alone or in combination with one or more other agents useful for therapy for a hypoproliferative cell disorder. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.

Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer cells that increases the resistance of the cancer cells to CTL mediated cytolysis and to Fas induced cell death. It is believed that blocking the transmission of the anti-apoptotic signal by B7-H1 increases the susceptibility of the cancer cells to apoptosis and CTL cytolysis thereby enhancing the death of cancer cells. Preferred compounds or B7-H1 antagonists include antibodies that bind to B7-H1, B7-H1 receptors, or ligands of B7-H1 such as PD-I or B7-1. Additional B7-H1 antagonists include small molecules, for example small molecules that bind the cytoplasmic portion of B7-H1 or the extracellular portion of B7-H1 and inhibit, reduce, block or interfere with B7-H1 signal transduction. Methods for treating one or more symptoms associated with cancer or hyperproliferation are also provided.

The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

Smac mimetics that inhibit IAPs.

The invention discloses a method for making natural gas by underground coal bed microorganism. Mainly, culture solution is utilized to cultivate and activate flora existing in the coal bed to convert underground methane flora into methane gas. The invention not only can convert coal into methane to serve as natural gas but also can improve the air permeability of the coal bed in the gas making process, so that the invention has an important meaning for improving the drainage capability of methane and ensuring upper safe extraction; more importantly, percent conversion is high, and converted coal bed resource can be reused so as to overcome the defects of the existing hot gasification method that percent conversion is low, and coal resource in the gasification area can not be reused after gasification ends.

The invention provides a method for the treatment of superficial bladder cancer and inflammatory diseases of the bladder which employs certain Toll-like Receptor (TLR)-agonists.

In this invention, the inventor discloses that naturally occurring IgM anti-lymphocyte antibodies bind to chemokine and non-chemokine receptors on lymphocytes and other cells, and downmodulate certain receptors including CD4 and CD2 on T cells and CD80 and CD86 on macrophages. The inventor also discloses that such antibodies (i) inhibit HIV-1 and other viruses from infecting cells (ii) inhibits activation and proliferation of T lymphocytes (iii) inhibits cytokine and chemokine production (iv) inhibits inflammatory processes, and (v) enhances death of malignant cells. This art or invention is novel in that the antibodies described herein are “naturally occurring” i.e. develop in absence of deliberate immunization and secondly these antibodies are distinct from disease causing autoantibodies in that these naturally occurring antibodies are polyreactive with low binding affinity.

A regulated heat source is described that can be applied to the nail bed in order to accelerate the death of the organisms know to contribute to nail bed infections

A regulated heat source is described that can be applied to the teeth and gums in order to accelerate the death of the bacterial or viral systems known to contribute to periodontal disease.

The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.

The present invention relates to a new molecular pathway in which activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy. Further, autophagic death is induced by caspase 8 inhibition and expression of the mammalian genes ATG7 and beclin.

Smac mimetics that inhibit IAPs.

The invention provides an important protein gene PTP1 relative with growth and infection of microsporidia of silkworms. The gene sequence CDS for coding the pole-tube protein PTP1 for microsporidia of silkworms is got based on the 9-magification gene data of microsporidia of silkworm and by collinear analysis. The pole-tube protein PTP1 got by the invention is of high importance for studying the breeding and infection mechanism of microsporidia, hence can play role in preventing and treating microsporidia in production practice. According RNAi interference, after the pole-tube protein PTP1 being interfered, the microsporidia loses the capability for infecting the host. The pole-tube protein PTP1 and its potential controlling gene of microsporidia will become a new factor for treating microsporidia infection. In addition, by means of transgenosis, the expression of the water-channel protein gene can be enriched, so that the water-channel protein gene can be used to control such destructive insects as locusts, etc.

The invention belongs to the biological medicine field, and relates to a fusion protein efficiently combined with a PD-1 and a VEGF, and a coding sequence and a use thereof. Specifically, the invention relates to the separated fusion protein comprising the following peptide fragments: (1) a human PD-L2 extracellular region peptide fragment; (2) a peptide fragment of a second immunoglobulin-like structural domain of a human FLT-1 extracellular region or / and a peptide fragment of a third immunoglobulin-like structural domain of a KDR extracellular region; and optionally (3) a human immunoglobulin Fc fragment. The fusion protein can inhibit the growth of tumor cells, promotes the death of the tumor cells, inhibits T cell inactivation, and enhances a tumor killing ability.

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data in deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a substantial change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.

The invention relates to a temperature self-regulating solar greenhouse system based on phase change heat storage technology. The temperature self-regulating solar greenhouse system comprises a phasechange heat storage wall, an automatic control mechanism, a solar collector, a collector outlet pipe, a collector return pipe, an electromagnetic inlet valve, a water inlet tee pipe, a water return tee pipe, a ground circulation pipeline, an electric heating and thermal insulation water tank and a cold water replenishment water tank. The temperature self-regulating solar greenhouse system based onthe phase change heat storage technology has the advantages that with the solar collector and the automatic control mechanism added on the basis of a traditional greenhouse system and a greenhouse brick wall structure improved into a phase change heat storage wall structure at the same time, the solar collector can effectively absorb solar heat during the day and conduct heating and heat storageto a greenhouse through water circulation; the greenhouse brick wall structure is used for regulating heat storage in the day and heat release at night in the greenhouse to realize stable indoor environment; the automatic control mechanism can conduct data collection and processing as well as automatic regulation of the greenhouse system so as to achieve energy-saving and environment-friendly effects and have positive significance for the development of greenhouse agriculture.

The invention discloses a corn straw silage feed preparing technology. A corn straw silage feed is prepared through the steps of preparing a silage pond, collecting and sorting silage feed raw materials, performing cutting-up, adding a feed additive, performing loading, closing over dry substances, performing film coating pretreatment, and performing earth coating for sealed storage. According tothe corn straw silage feed prepared by the corn straw silage feed preparing technology disclosed by the invention, the content of a hazardous substance, namely flavatin, in the feed is reduced, the mildew and rot rate of the feed is reduced, and the mouth feel and the quality of the feed are improved; besides, the silage feed is not liable to decompose due to silage, the silage loading void content is reduced, and favorable anaerobic environment can be created for lactic acid bacteria fermentation, so that fermentation is facilitated; a layer of the dry substances are covered, so that the situation that a large quantity of nutrient components run off along with moisture is avoided, nutrient loss is reduced, and the fragrance of lactic acid of the silage is improved; and the feed additive is added, so that the quality of the silage feed can be improved, the food consumption of the feed is increased, and the palatability of the feed is strengthened.

The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LySB3,GluB29 insulin to patients in need of this treatment.

The invention relates to the structure of radioactive micro balls and a preparation method. At least one micro ball having isotopes which can radiate beta or gamma-ray is added in a biocompatible substance; and the biocompatible substance represents biological materials and chemical materials which can be used for the clinical cure: biologic glass, biologic ceramics, biologic resin and liposome, etc. The preparation method comprises the steps: 1. activation method: putting phosphorus or yttrium-containing into an irradiation container of an atom reacting device, and irradiating the micro balls with neutron, so that the phosphorus or the yttrium is activated to be radioactive phosphorus (32P) or radioactive yttrium (90Y); and 2. mixing method: mixing isotope (such as 125I and 103Pd) which has radiate beta or gamma- ray with entitative or hollow micro balls, carrying the isotopes into human bodies by taking the micro balls as the carrier of the isotope for the radiotherapy of tumor. The radioactive micro balls have the volume which is in the range of nanometer and micrometer, and can release beta or gamma ray; and the isotope is one or several, has short radiation range, reduces the side effects of the radiotherapy of the tumor, and can be induced into the human bodies by means of local intervention or surgery through blood vessels.

Smac mimetics that inhibit IAPs.